Infantile hydrocephalus: management using CT assessment

Free-floating bone flap posterior cranial vault release in syndromic craniosynostosis

The aim of this study was to investigate the efficacy of non-detachable free-floating bone flap posterior cranial vault release (FFBF-PCVR) in syndromic craniosynostosis. A retrospective review was completed of subjects who underwent FFBF-PCVR at 4 time-points: within 3 months preoperatively, 7 days postoperatively, 3 months postoperatively and at the last follow-up postoperatively. Volumetric and craniometric data, the ratio of ventricular diameter, and the cerebellar tonsillar descent were measured after FFBF-PCVR by using computed tomographic and magnetic resonance imaging. A total of 19 patients underwent FFBF-PCVR. The mean age was 11.7 months (range 4-36 months). The mid cranial height, posterior cranial height, and anterior posterior diameter length significantly increased from preoperative to postoperative 7 days, from postoperative 7 days to postoperative3 months, and from postoperative 3 months to the last follow-up. There was a significant increase in pre- to 7 days postoperative intracranial volume (1195.21 ± 246.56 cm³, p < 0.001; respectively), 3 months postoperative intracranial volume (1228.03 ± 249.61 cm³, p < 0.001; respectively), and intracranial volume at last follow-up (1390.25 ± 219.99 cm³, p < 0.001; respectively). There was a significant increase in 7 days' postoperative to 3 months' postoperative intracranial volume (p < 0.001; respectively), and intracranial volume at last follow-up (p < 0.001; respectively). There was a significant increase in 3 months postoperative to intracranial volume at last follow-up (p < 0.001). The mean intracranial volume increased by an average of 36.6 percent (range, 18.1 to 79.2 percent) at last follow-up. The degree of hydrocephalus in the preoperative child was (45.77% ± 9.17%), and at the last follow-up after surgery, the degree of hydrocephalus was (35.02 ± 9.50%), p < 0.01). Preoperatively, 14 patients (73.7 percent) had radiographic evidence of Chiari malformation type I. The cerebellar tonsillar descent, measured using pre- and postoperative MRI, decreased in all patients after FFBF-PCVR (preoperative: 7.5 ± 1.4 mm, postoperative: 5.3 ± 1.7 mm; p = 0.001). FFBF-PCVR can efficiently expand the posterior cranial vault with only one surgical procedure. Moreover, it helps to relieve hydrocephalus and cerebellar tonsillar herniation.

Giant Occipital Encephalocele - Challenges in Management

INTRODUCTION

Giant occipital encephalocele (GOE) is a term used when the size of the OE is greater than or equal to the size of the head. It has been limited to case reports, with only sporadic exclusive series. This is a series of GOE managed at our center over time with emphasis on practical problems faced in management.

MATERIALS AND METHODS

This was a retrospective observational study. The patients were evaluated for the age of presentation, sex, and head size. Any associated neural tube defect was also looked for. Imaging was used for associated brain anomalies and to plan the surgical procedure. The requirement of ventriculoperitoneal (VP) shunt was also assessed.

RESULTS

During the study period of 7 years, 11 patients of GOE were admitted. Apart from one, all other patients were <1 year of age. Nine patients underwent surgical intervention, which included excision and repair of swelling with or without VP shunt placement. The content of the sac was only cerebrospinal fluid (CSF) in six patients and CSF and gliotic brain tissue in remaining patients. The attendants of two patients did not give consent for surgery and left against medical advice.

CONCLUSION

GOE is an uncommon entity with limited information about management. Careful evaluation, proper imaging of patient, and care during intraoperative and postoperative periods with emphasis of factors determining the prognosis may provide satisfactory results.

Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: Management of posthemorrhagic hydrocephalus in premature infants

OBJECT

The objective of this systematic review and analysis was to answer the following question: What are the optimal treatment strategies for posthemorrhagic hydrocephalus (PHH) in premature infants?

METHODS

Both the US National Library of Medicine and the Cochrane Database of Systematic Reviews were queried using MeSH headings and key words relevant to PHH. Two hundred thirteen abstracts were reviewed, after which 98 full-text publications that met inclusion criteria that had been determined a priori were selected and reviewed.

RESULTS

Following a review process and an evidentiary analysis, 68 full-text articles were accepted for the evidentiary table and 30 publications were rejected. The evidentiary table was assembled linking recommendations to strength of evidence (Classes I-III).

CONCLUSIONS

There are 7 recommendations for the management of PHH in infants. Three recommendations reached Level I strength, which represents the highest degree of clinical certainty. There were two Level II and two Level III recommendations for the management of PHH. Recommendation Concerning Surgical Temporizing Measures: I. Ventricular access devices (VADs), external ventricular drains (EVDs), ventriculosubgaleal (VSG) shunts, or lumbar punctures (LPs) are treatment options in the management of PHH. Clinical judgment is required.

STRENGTH OF RECOMMENDATION

Level II, moderate degree of clinical certainty. Recommendation Concerning Surgical Temporizing Measures: II. The evidence demonstrates that VSG shunts reduce the need for daily CSF aspiration compared with VADs.

STRENGTH OF RECOMMENDATION

Level II, moderate degree of clinical certainty. Recommendation Concerning Routine Use of Serial Lumbar Puncture: The routine use of serial lumbar puncture is not recommended to reduce the need for shunt placement or to avoid the progression of hydrocephalus in premature infants.

STRENGTH OF RECOMMENDATION

Level I, high clinical certainty. Recommendation Concerning Nonsurgical Temporizing Agents: I. Intraventricular thrombolytic agents including tissue plasminogen activator (tPA), urokinase, or streptokinase are not recommended as methods to reduce the need for shunt placement in premature infants with PHH.

STRENGTH OF RECOMMENDATION

Level I, high clinical certainty. Recommendation Concerning Nonsurgical Temporizing Agents. II. Acetazolamide and furosemide are not recommended as methods to reduce the need for shunt placement in premature infants with PHH.

STRENGTH OF RECOMMENDATION

Level I, high clinical certainty. Recommendation Concerning Timing of Shunt Placement: There is insufficient evidence to recommend a specific weight or CSF parameter to direct the timing of shunt placement in premature infants with PHH. Clinical judgment is required.

STRENGTH OF RECOMMENDATION

Level III, unclear clinical certainty. Recommendation Concerning Endoscopic Third Ventriculostomy: There is insufficient evidence to recommend the use of endoscopic third ventriculostomy (ETV) in premature infants with posthemorrhagic hydrocephalus.

STRENGTH OF RECOMMENDATION

Level III, unclear clinical certainty.